ArticleBMJ (Clinical research ed.)1999
Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis.
Article in BMJ (Clinical research ed.), 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 85 citations in OpenAlex.
- How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review.Neurology and therapy · 2021Review
- Modelling the cost effectiveness of disease-modifying treatments for multiple sclerosis: issues to consider.PharmacoEconomics · 2013Review
- Hospitalization rates and discharge status in multiple sclerosis.Multiple sclerosis international · 2013Article
- Cost-effectiveness of disease-modifying therapies in multiple sclerosis.Current neurology and neuroscience reports · 2012Review
- Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature.Autoimmune diseases · 2012Article
- Review
- Assessing cost-effectiveness in the management of multiple sclerosis.ClinicoEconomics and outcomes research : CEOR · 2009Article
- Direct and indirect costs of Multiple Sclerosis in Baix Llobregat (Catalonia, Spain), according to disability.BMC health services research · 2006Article
- Costs and quality of life of patients with multiple sclerosis in Europe.Journal of neurology, neurosurgery, and psychiatry · 2006Article
- Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.CNS drugs · 2004Review
- The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment.CNS drugs · 2004Review
- Cost-analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents.Clinical drug investigation · 2004Article
- Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.BMJ (Clinical research ed.) · 2003Article
- Review
- Disease-modifying Therapies for Multiple Sclerosis.Current treatment options in neurology · 2003Article
- Efficacy, safety, and cost of new anticancer drugs. Pessimistic conclusion was not justified.BMJ (Clinical research ed.) · 2002Article
- Creating an integrated public sector? Labour's plans for the modernisation of the English health care system.International journal of integrated care · 2002Article
- Disease modifying treatment in multiple sclerosis.Journal of neurology, neurosurgery, and psychiatry · 2001Article
- Cost-effectiveness analysis of inhaled zanamivir in the treatment of influenza A and B in high-risk patients.PharmacoEconomics · 2001Article
- Drug treatment of multiple sclerosisThe Western journal of medicine · 2000Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the cost utility of interferon beta-1b in secondary progressive multiple sclerosis.
designPopulation based cost utility model (healthcare perspective). Data on use of health services were obtained from case records and routine morbidity data and utility values from a EuroQol survey. Local and published costs were used. Effectiveness was modelled using data on relative risk reductions from a randomised trial of interferon beta-1b.
settingTayside region, 1993-5. SUBJECTS: 132 ambulatory people with secondary progressive multiple sclerosis.
main outcome measuresCost per quality adjusted life year (QALY) gained. Rate of relapse and proportion becoming wheelchair dependent over three years.
resultsThe number needed to treat for 30 months to delay time to wheelchair dependence in one person by nine months was 18 (95% confidence interval 5 to 26). For every 18 people treated for 30 months, six relapses would be prevented, gaining 0.397 discounted QALYs. The cost per QALY gained was 1 024 667 pounds sterling (276 466 pounds sterling to 485 499 pound sterling). If treatment was restricted to patients attending neurology services, the number needed to treat was 14 (cost per QALY gained 833 pounds sterling 514 (161 358 pounds sterling to infinity)). The cost per QALY gained was not sensitive to changes in cost which took account of a societal perspective.
conclusionsThe cost per QALY gained from interferon beta is high because of the high drug cost and modest clinical effect. Resources could be used more efficiently elsewhere.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.